BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

626 related articles for article (PubMed ID: 30092555)

  • 1. Everolimus-based combination therapies for HR+, HER2- metastatic breast cancer.
    O'Shaughnessy J; Thaddeus Beck J; Royce M
    Cancer Treat Rev; 2018 Sep; 69():204-214. PubMed ID: 30092555
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Everolimus plus Exemestane for Hormone Receptor-Positive Advanced Breast Cancer: A PAM50 Intrinsic Subtype Analysis of BOLERO-2.
    Prat A; Brase JC; Cheng Y; Nuciforo P; Paré L; Pascual T; Martínez D; Galván P; Vidal M; Adamo B; Hortobagyi GN; Baselga J; Ciruelos E
    Oncologist; 2019 Jul; 24(7):893-900. PubMed ID: 30679318
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of everolimus plus exemestane in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: Results of the single-arm, phase IIIB 4EVER trial.
    Tesch H; Stoetzer O; Decker T; Kurbacher CM; Marmé F; Schneeweiss A; Mundhenke C; Distelrath A; Fasching PA; Lux MP; Lüftner D; Hadji P; Janni W; Muth M; Kreuzeder J; Quiering C; Taran FA
    Int J Cancer; 2019 Feb; 144(4):877-885. PubMed ID: 29992557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis.
    Giuliano M; Schettini F; Rognoni C; Milani M; Jerusalem G; Bachelot T; De Laurentiis M; Thomas G; De Placido P; Arpino G; De Placido S; Cristofanilli M; Giordano A; Puglisi F; Pistilli B; Prat A; Del Mastro L; Venturini S; Generali D
    Lancet Oncol; 2019 Oct; 20(10):1360-1369. PubMed ID: 31494037
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of everolimus with exemestane vs. exemestane alone in elderly patients with HER2-negative, hormone receptor-positive breast cancer in BOLERO-2.
    Pritchard KI; Burris HA; Ito Y; Rugo HS; Dakhil S; Hortobagyi GN; Campone M; Csöszi T; Baselga J; Puttawibul P; Piccart M; Heng D; Noguchi S; Srimuninnimit V; Bourgeois H; Gonzalez Martin A; Osborne K; Panneerselvam A; Taran T; Sahmoud T; Gnant M
    Clin Breast Cancer; 2013 Dec; 13(6):421-432.e8. PubMed ID: 24267730
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Everolimus versus alpelisib in advanced hormone receptor-positive HER2-negative breast cancer: targeting different nodes of the PI3K/AKT/mTORC1 pathway with different clinical implications.
    Vernieri C; Corti F; Nichetti F; Ligorio F; Manglaviti S; Zattarin E; Rea CG; Capri G; Bianchi GV; de Braud F
    Breast Cancer Res; 2020 Apr; 22(1):33. PubMed ID: 32252811
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Everolimus Plus Exemestane vs Everolimus or Capecitabine Monotherapy for Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer: The BOLERO-6 Randomized Clinical Trial.
    Jerusalem G; de Boer RH; Hurvitz S; Yardley DA; Kovalenko E; Ejlertsen B; Blau S; Özgüroglu M; Landherr L; Ewertz M; Taran T; Fan J; Noel-Baron F; Louveau AL; Burris H
    JAMA Oncol; 2018 Oct; 4(10):1367-1374. PubMed ID: 29862411
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progression-free survival with endocrine-based therapies following progression on non-steroidal aromatase inhibitor among postmenopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative metastatic breast cancer: a network meta-analysis.
    Ayyagari R; Tang D; Patterson-Lomba O; Zhou Z; Xie J; Chandiwana D; Dalal AA; Niravath PA
    Curr Med Res Opin; 2018 Sep; 34(9):1645-1652. PubMed ID: 29781326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer: results of phase IIIb BALLET trial in Spain.
    Ciruelos E; Vidal M; Martínez de Dueñas E; Martínez-Jáñez N; Fernández Y; García-Sáenz JA; Murillo L; Carabantes F; Beliera A; Fonseca R; Gavilá J
    Clin Transl Oncol; 2018 Jun; 20(6):753-760. PubMed ID: 29116433
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial.
    Park YH; Kim TY; Kim GM; Kang SY; Park IH; Kim JH; Lee KE; Ahn HK; Lee MH; Kim HJ; Kim HJ; Lee JI; Koh SJ; Kim JY; Lee KH; Sohn J; Kim SB; Ahn JS; Im YH; Jung KH; Im SA;
    Lancet Oncol; 2019 Dec; 20(12):1750-1759. PubMed ID: 31668850
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Phase II Open Label Study of Everolimus in Combination With Endocrine Therapy in Resistant Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer.
    Yardley DA; Liggett W; Mainwaring M; Castrellon A; Blakely L; Hemphill B; Anz B; Young RR; Shastry M; DeBusk LM; Hainsworth JD; Burris HA
    Clin Breast Cancer; 2020 Apr; 20(2):89-97. PubMed ID: 31932237
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of the combination of metformin, everolimus and exemestane in overweight and obese postmenopausal patients with metastatic, hormone receptor-positive, HER2-negative breast cancer: a phase II study.
    Yam C; Esteva FJ; Patel MM; Raghavendra AS; Ueno NT; Moulder SL; Hess KR; Shroff GS; Hodge S; Koenig KH; Chavez Mac Gregor M; Griner RL; Yeung SJ; Hortobagyi GN; Valero V
    Invest New Drugs; 2019 Apr; 37(2):345-351. PubMed ID: 30610588
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative efficacy of everolimus plus exemestane versus fulvestrant for hormone-receptor-positive advanced breast cancer following progression/recurrence after endocrine therapy: a network meta-analysis.
    Bachelot T; McCool R; Duffy S; Glanville J; Varley D; Fleetwood K; Zhang J; Jerusalem G
    Breast Cancer Res Treat; 2014 Jan; 143(1):125-33. PubMed ID: 24272078
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of Palbociclib Combinations in Hormone Receptor-Positive Metastatic Breast Cancer Patients After Prior Everolimus Treatment.
    Dhakal A; Matthews CM; Levine EG; Salerno KE; Zhang F; Takabe K; Early AP; Edge SB; O'Connor T; Khoury T; Young JS; Opyrchal M
    Clin Breast Cancer; 2018 Dec; 18(6):e1401-e1405. PubMed ID: 29778787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A new era of improving progression-free survival with dual blockade in postmenopausal HR(+), HER2(-) advanced breast cancer.
    Jerusalem G; Bachelot T; Barrios C; Neven P; Di Leo A; Janni W; de Boer R
    Cancer Treat Rev; 2015 Feb; 41(2):94-104. PubMed ID: 25575443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of everolimus plus exemestane in patients with HR+, HER2- advanced breast cancer progressing on/after prior endocrine therapy in routine clinical practice: Primary results from the non-interventional study, STEPAUT.
    Steger GG; Egle D; Bartsch R; Pfeiler G; Petru E; Greil R; Helfgott R; Marth C; Öhler L; Hubalek M; Lang A; Tinchon C; Haslbauer F; Redl A; Hock K; Hennebelle M; Mraz B; Gnant M
    Breast; 2020 Apr; 50():64-70. PubMed ID: 32062536
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment landscape of advanced breast cancer patients with hormone receptor positive HER2 negative tumors - Data from the German PRAEGNANT breast cancer registry.
    Hartkopf AD; Huober J; Volz B; Nabieva N; Taran FA; Schwitulla J; Overkamp F; Kolberg HC; Hadji P; Tesch H; Häberle L; Ettl J; Lux MP; Lüftner D; Wallwiener M; Müller V; Beckmann MW; Belleville E; Wimberger P; Hielscher C; Geberth M; Fersis N; Abenhardt W; Kurbacher C; Wuerstlein R; Thomssen C; Untch M; Fasching PA; Janni W; Fehm TN; Wallwiener D; Brucker SY; Schneeweiss A
    Breast; 2018 Feb; 37():42-51. PubMed ID: 29100043
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.
    Johnston S; Pippen J; Pivot X; Lichinitser M; Sadeghi S; Dieras V; Gomez HL; Romieu G; Manikhas A; Kennedy MJ; Press MF; Maltzman J; Florance A; O'Rourke L; Oliva C; Stein S; Pegram M
    J Clin Oncol; 2009 Nov; 27(33):5538-46. PubMed ID: 19786658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Health-related quality of life and disease symptoms in postmenopausal women with HR(+), HER2(-) advanced breast cancer treated with everolimus plus exemestane versus exemestane monotherapy.
    Campone M; Beck JT; Gnant M; Neven P; Pritchard KI; Bachelot T; Provencher L; Rugo HS; Piccart M; Hortobagyi GN; Nunzi M; Heng DY; Baselga J; Komorowski A; Noguchi S; Horiguchi J; Bennett L; Ziemiecki R; Zhang J; Cahana A; Taran T; Sahmoud T; Burris HA
    Curr Med Res Opin; 2013 Nov; 29(11):1463-73. PubMed ID: 23962028
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Everolimus Plus Letrozole for Treatment of Patients With HR
    Safra T; Kaufman B; Kadouri L; Efrat Ben-Baruch N; Ryvo L; Nisenbaum B; Evron E; Yerushalmi R
    Clin Breast Cancer; 2018 Apr; 18(2):e197-e203. PubMed ID: 29097108
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.